Carvedilol
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | COREG | — | 1997-05-29 – 2007-02-23 | fda.gov ↗ |
| Approved | US (FDA) | COREG | — | 1995-09-14 | fda.gov ↗ |
Trials 136 · started per year
Also used as a comparator or background therapy in 87 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06108518 Comparator | Jun → Oct 2024 | rheumatoid arthritis | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT06643221 Comparator | Jan 2018 → May 2031 expected | leukemia, lymphoma | University of Arizona | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06304896 Comparator | May 2024 → May 2025 | chemotherapy-induced toxicity | Arab Contractors Medical Centre | Unknown | No outcome recorded |
| Phase 1 | NCT02907021 Background | Nov 2016 → Apr 2018 | breast cancer, heart failure | Population Health Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06836856 Comparator | Jan → Jun 2025 overdue | traumatic brain injury | Mansoura University | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04190433 Background | Sep 2020 → Apr 2023 | breast carcinoma, lymphoma, sarcoma | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT02230891 Comparator | Oct 2014 → Dec 2020 | diabetes mellitus, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01221792 Comparator | Oct 2010 → Jun 2011 | post-traumatic stress disorder | Columbia Northwest Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT01171183 Comparator | Aug 2010 → May 2014 | cocaine dependence, substance withdrawal syndrome | University of Arkansas | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06696248 Background | Nov 2024 → Sep 2025 overdue | portal hypertension | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06470386 Comparator | Jun 2024 → Nov 2025 | portal hypertension | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03720067 Comparator | Jan 2019 → Dec 2020 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT05931276 Comparator | May 2024 → Dec 2026 expected | end stage renal failure | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 3 | NCT06853951 Comparator | Jul 2023 → Mar 2025 overdue | chemotherapy-induced toxicity | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT05849766 Comparator | Apr 2023 → May 2024 | dilated cardiomyopathy | October 6 University | Completed | No outcome recorded |
| Phase 3 | NCT04345796 Comparator | Feb 2021 → Jun 2024 | tricuspid valve insufficiency | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02066649 Comparator | Jul 2018 → Mar 2019 | portal hypertension | Rutgers, The State University of New Jersey | Withdrawn | No outcome recorded |
| Phase 3 | NCT01724450 Comparator | Apr 2013 → Jun 2017 | breast cancer, chemotherapy-induced toxicity, heart failure | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01413048 Comparator | Jan 2011 → Mar 2012 | essential hypertension | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT00657241 Comparator | Apr 2008 → Apr 2010 | hypertensive disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT00589303 Comparator | Dec 2007 → Jul 2011 | atrial fibrillation, heart failure | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT00313157 Comparator | Apr 2006 → Sep 2010 | atrial fibrillation | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00323037 Comparator | Mar 2006 → Apr 2008 | congestive heart failure | CTI-1, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00493480 Comparator | Sep 2003 → Aug 2009 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 440 trials | ||||||
| Phase 4 | NCT07521332 Background | Apr 2026 → Apr 2027 expected | cirrhosis of liver, esophageal varices, hepatic encephalopathy, portal hypertension +1 | Asian Institute Of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07322237 Comparator | Apr 2026 → Jan 2029 expected | cardiovascular-kidney-metabolic syndrome, cirrhosis of liver, cirrhotic cardiomyopathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT07298993 Comparator | Feb 2026 → Apr 2029 expected | heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07103655 Background | Jan → Jul 2026 overdue | hypertrophic cardiomyopathy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07352228 Comparator | Jan → Sep 2026 expected | portal hypertension | Xijing Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07238452 Comparator | Dec 2025 → Dec 2032 expected | atrial fibrillation, symptomatic heart failure | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06594783 Comparator | Jan 2025 → Oct 2030 expected | cirrhosis of liver, esophageal varices | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 4 | NCT06594744 Comparator | Oct 2024 → Oct 2030 expected | esophageal varices, hepatocellular carcinoma | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 4 | NCT07397481 Comparator | Mar 2024 → Mar 2025 | cirrhosis of liver, hypertensive disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04049786 Comparator | Jun 2019 → Aug 2022 | obesity disorder | Natalia Valadares de Moraes | Unknown | No outcome recorded |
| Phase 4 | NCT05872698 Comparator | Apr 2019 → Dec 2026 expected | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | King's College Hospital NHS Trust | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03646357 Comparator | Oct 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02945982 Background | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02907749 Background | Jan 2018 → Jan 2020 | cirrhosis of liver, portal hypertension | Changqing Yang | Completed | No outcome recorded |
| Phase 4 | NCT02809820 Comparator | May → Dec 2016 | acute coronary syndrome | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT02638415 Background | Dec 2015 → Jun 2018 | cirrhosis of liver, esophageal varices | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01383044 Comparator | Jul 2011 → Jul 2015 | esophageal varices with bleeding | E-DA Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01354444 Comparator | Jun 2011 → Dec 2016 | Alzheimer disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02056626 Comparator | Mar 2011 → Nov 2018 | hypertensive disorder | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT01425164 Comparator | Jan 2011 → Jun 2012 | coronary artery disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01155635 Comparator | Jul 2010 → Jun 2015 | myocardial infarction | Takeshi Morimoto | Completed | No outcome recorded |
| Phase 4 | NCT00827775 Comparator | Jun 2009 → Sep 2010 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00673075 Comparator | May 2008 → Sep 2009 | coronary artery disorder, hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00496834 Comparator | Feb 2008 → Sep 2009 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00517725 Comparator | Jul 2007 → May 2010 | congestive heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 4 | NCT00433043 Comparator | Jan 2007 → May 2009 | congestive heart failure | St. Luke's-Roosevelt Hospital Center | Terminated | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00924833 Comparator | May → Nov 2006 | altitude sickness, heart failure | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 4 | NCT01103154 Comparator | Mar 2005 → Jan 2010 | esophageal varices with bleeding | E-DA Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00642434 Comparator | Jan 2004 → Jun 2008 | type 2 diabetes mellitus | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT01070641 Comparator | Jun 2002 → Feb 2011 | portal hypertension | Aga Khan University | Unknown | No outcome recorded |
| Phase 4 | NCT01798992 Comparator | Sep 2000 → Mar 2009 | non-familial dilated cardiomyopathy | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07445334 Comparator | Mar 2026 → Sep 2027 expected | cardiac rhythm disease | Western Sydney Local Health District | Not yet recruiting | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06930092 Comparator | Aug 2025 → Apr 2028 expected | cardiomyopathy | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT07111221 Background | Jun 2025 → Oct 2029 expected | cirrhosis of liver, portal hypertension | Medical University of Warsaw | Recruiting | No outcome recorded |
| — | NCT07108075 Background | Jun → Oct 2025 overdue | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT06431919 Background | Jun 2025 → Jan 2028 expected | acute kidney injury, cirrhosis of liver, cirrhotic cardiomyopathy, diastolic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| — | NCT06836778 Background | Feb 2025 → Jan 2026 overdue | hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT06041932 Background | Nov 2023 → Aug 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05553717 Comparator | Oct 2022 → Oct 2023 | esophageal ulcer, myocardial ischemia | Tanta University | Unknown | No outcome recorded |
| — | NCT04254822 Background | Jun 2020 → Dec 2023 | cirrhosis of liver, esophageal varices with bleeding | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT02619526 Comparator | Dec 2016 → Jul 2018 | heart failure | Dong-A University | Unknown | No outcome recorded |
| — | NCT01659346 Comparator | Feb 2016 → Dec 2017 | hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT02465645 Comparator | Jun 2015 → Jan 2017 | esophageal varices | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02137733 Comparator | Jun 2013 → May 2016 | heart failure | Mebix Inc | Unknown | No outcome recorded |
| — | NCT01586156 Comparator | Dec 2012 → Jul 2016 | pulmonary hypertension | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT01608893 Comparator | May 2012 → Jun 2025 | atrial fibrillation | University of Calgary | Unknown | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00878384 Comparator | Apr 2009 → Jun 2012 | atrial fibrillation, heart failure | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00566969 Comparator | Sep 2007 → Dec 2012 | cocaine dependence, opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-09-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval And Shipment Of Generic Coreg® Tablets tevapharm.com ↗ |
| 2004-06-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Carvedilol Tablets tevapharm.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 226 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carvedilol | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗218“The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing...” NCT00442923 ↗ “Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol...” PMID 39645270 ↗ Aug 2024 “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “including the beta-blocker, carvedilol, and the ACE-I, ramipril, as tolerated, at the maximum doses tolerated, up to carvedilol 25mg BID and ramipril 10mg once daily” NCT02907021 ↗ “All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗ “Carvedilol will be the preferred nonselective beta-blocker, starting at 6.25 mg once daily and increasing to 12.5 mg once daily after 1 week if tolerated.” NCT07587671 ↗ “If sotalol is contraindicated, an alternative BB may be initiated using standard doses e.g. metoprolol, atenolol, bisoprolol, carvedilol.” NCT07445334 ↗ “Significant reduction of portal pressure is observed in up to 50% of patients treated with propranolol and up to 75% with carvedilol.” NCT07111221 ↗ “Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.” PMID 31305281 ↗ Jul 2020 “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ “betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol” NCT03596385 ↗ “representative drugs including bisoprolol, metoprolol sustained-release tablets, and carvedilol” NCT07335900 ↗ “evidence-based beta-blockers (extended-release metoprolol succinate, bisoprolol, carvedilol)” NCT07238452 ↗ “Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol” NCT04575675 ↗ “Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)” NCT04977180 ↗ “Carvedilol controlled release is a marketed drug to treat high blood pressure.” NCT00537043 ↗ “Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session.” NCT03361280 ↗ “carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop” NCT02200822 ↗ “Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg” NCT00911508 ↗ “Beta blocker: carvedilol, metroprolol, bisoprolol or nebivolol” NCT07513883 ↗ “penbutolol pindolol, carvedilol, labetalol, benazepril” NCT00684489 ↗ “Carvedilol 50mg/d (100mg/d if weight is > 85kg)” NCT02817360 ↗ “* Carvedilol up to a total dose of 50mg daily” NCT03646357 ↗ “a beta-blocker (carvedilol or bisoprolol)” NCT06930092 ↗ “* metoprolol * atenolol * carvedilol” NCT00589303 ↗ “Carvedilol, target dose: 50 mg daily” NCT04221919 ↗ “Carvedilol 3.125-50mg b.d.” NCT00878384 ↗ “carvedilol (Coreg)” NCT00000620 ↗ “Carvedilol 6.25mg” NCT00578617 ↗ “carvedilol” NCT04767061 ↗ “Carvedilol” NCT06853951 ↗ “Carvedilol” NCT00741585 ↗ “carvedilol” NCT04757584 ↗ |
| Known as | carvedilol (Coreg) | “carvedilol (Coreg)” NCT00000620 ↗ |
| Known as | Carvedilol Controlled Release (CR) | “Drug: Carvedilol Controlled Release (CR)” NCT00430040 ↗ |
| Known as | Carvedilol CR | “Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at...” NCT00430040 ↗3“Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.” NCT00524134 ↗ “once-daily extended-release carvedilol (carvedilol CR) combined with the ACEI lisinopril” PMID 20883227 ↗ Jul 2010 “Drug: Carvedilol CR” NCT00657241 ↗ |
| Known as | carvedilol slow-release (SR) | “carvedilol slow-release (SR)” NCT05553314 ↗ |
| Known as | carvedilol-SR | “The objective of this trial is to evaluate the effect of sustained-release carvedilol (carvedilol-SR) on the outcome [N-terminal pro-B-natriuretic peptide (NT-proBNP)...” PMID 38737708 ↗ Apr 2024 |
| Known as | Carvid | “Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®” NCT05849766 ↗1“Carvid (carvedilol)” NCT06836856 ↗ |
| Known as | Coreg | “The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x...” NCT00650416 ↗7“The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x...” NCT00648622 ↗ “The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release...” NCT00272805 ↗ “Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in...” NCT05872698 ↗ “The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.” NCT00508365 ↗ “mortality benefits (carvedilol \[Coreg\] 25 mg bid, metoprolol succinate \[Toprol-XL\] 200 mg qd)” NCT00433043 ↗ “commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals)” NCT00834795 ↗ “commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals)” NCT00834873 ↗ |
| Known as | COREG CR | “20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR)” NCT00347360 ↗ |
| Known as | CVD | “CECCY trial demonstrated that the β-blocker carvedilol (CVD) could attenuate myocardial injury secondary to ANT.” PMID 35087624 ↗ Jan 2022 |
| Known as | Dilatrend | “Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ |
| Known as | Dilatrend SR | “Carvedilol SR (Dilatrend SR; 8/16/32/64 mg) once daily, starting at 32 mg and up-titrated to maximal tolerated dose (up to 128 mg).” NCT07577518 ↗ |
| Known as | Dilatrend Tab | “Dilatrend Tab® (carvedilol) 12.5 mg” NCT00496834 ↗ |
| Action | Inhibit | “blockage of adrenergic receptors by carvedilol” NCT00000294 ↗ |
| Modality | Other / unclassified | “Carvedilol and bisoprolol are established beta-blockers for treating hypertension or chronic heart failure” NCT01243827 ↗ |
| Route | Oral | “a single oral dose of low (25mg) or high dose of carvedilol (50mg)” NCT00000294 ↗ |